2023
“Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation
Chen P, Gorshein E, Tormey C, Siddon A, Perincheri S. “Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation. American Journal Of Hematology 2023, 98: 984-988. PMID: 36688500, DOI: 10.1002/ajh.26856.Peer-Reviewed Educational Materials
2022
Recognizing the microgranular variant of acute promyelocytic leukemia when considering leukapheresis
Gisriel S, Chen P, Tormey C, Siddon A. Recognizing the microgranular variant of acute promyelocytic leukemia when considering leukapheresis. Transfusion 2022, 63: 277-278. PMID: 36426743, DOI: 10.1111/trf.17195.Peer-Reviewed Original Research
2020
A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance
Mendoza H, Chen PH, Pine AB, Siddon AJ, Bale AE, Gowda L, Killie A, Richards J, Varin-Tremblay C, Kloss R, Podoltsev NA. A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance. Leukemia & Lymphoma 2020, 62: 1251-1254. PMID: 33345654, DOI: 10.1080/10428194.2020.1861276.Peer-Reviewed Case Reports and Technical NotesExpression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions
Chen PH, Bossuyt V, Reisenbichler E. Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions. Human Pathology 2020, 108: 68-75. PMID: 33245988, DOI: 10.1016/j.humpath.2020.11.009.Peer-Reviewed Original ResearchConceptsMalignant phyllodes tumorPhyllodes tumorBenign tumorsLymphoid enhancer-binding factor 1Fibroepithelial lesionsTissue microarrayEnhancer-binding factor 1LEF-1 expressionMalignant tumorsBorderline/malignant phyllodes tumorsΒ-cateninStromal componentsNuclear expressionWorld Health Organization criteriaMetastatic phyllodes tumorWnt/β-catenin pathway activationAlternative treatment optionBorderline phyllodes tumorWnt/β-catenin pathwayFactor 1Β-catenin pathway activationE-cadherin immunohistochemistryWnt/β-catenin signalingΒ-catenin pathwayNuclear β-catenin stainingBilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing
Chen PH, Hui P, Buza N. Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing. International Journal Of Gynecological Pathology 2020, 39: 193-198. PMID: 30676431, DOI: 10.1097/pgp.0000000000000579.Peer-Reviewed Case Reports and Technical NotesConceptsSignet-ring stromal tumorStromal tumorsNext-generation sequencing analysisBilateral solid ovarian tumorsBilateral ovarian massesFOXL2 mutation testingSolid ovarian tumorSignet ring cell morphologySmooth muscle actinUnderlying genetic abnormalitiesPCR-Sanger sequencingNuclear beta-catenin expressionHandful of casesHeterogenous pathogenesisAbdominal distentionRectal bleedingTotal hysterectomyStromal neoplasmsOvarian massesOvarian tumorsCase reportBeta-catenin expressionSequencing analysisMuscle actinTumors
2019
Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx
Chen PH, Yang Y, O'Malley DP, Xu ML. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Annals Of Diagnostic Pathology 2019, 41: 129-135. PMID: 31247533, DOI: 10.1016/j.anndiagpath.2019.06.007.Peer-Reviewed Original ResearchConceptsB-cell non-Hodgkin lymphomaEBV-negative casesAggressive B-NHLPD-L1Peptide receptor radionuclide therapyAggressive B-cell lymphomasEBV-positive DLBCLEBV-positive patientsDisease-free intervalPrimary clinical outcomeYear of diagnosisEBV-positive casesReceptor radionuclide therapyExpression of SSTR2Non-Hodgkin lymphomaExpression of CD30Five yearsAvailable outcome dataB-cell lymphomaEBV negativityInitial therapyClinicopathologic characteristicsBetter prognosisCase seriesClinical outcomes